These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Criteria for initiating highly active antiretroviral therapy and short-term immune response among HIV-1-infected patients in Côte d'Ivoire.
    Author: Diabaté S, Alary M.
    Journal: HIV Med; 2009 Nov; 10(10):640-6. PubMed ID: 19659945.
    Abstract:
    OBJECTIVES: The aims of this study were to determine the predictors of CD4 count below 200 cells/microL and to propose an algorithm for antiretroviral therapy initiation; and to assess the determinants of immune response to highly active antiretroviral therapy (HAART) in Côte d'Ivoire. METHODS: A total of 615 consecutive patients attending an HIV/AIDS day hospital were enrolled in the study. We constructed a score system based on the results of a multivariate logistic regression analysis of the predictors of CD4 count <200 cells/microL with the intention of proposing an algorithm able to accurately designate patients eligible for HAART. We also identified factors associated with a short-term increase in CD4 count >50 cells/microL after HAART initiation. RESULTS: Total lymphocyte count <1200 cells/microL (P<0.0001), lower haemoglobin levels (P<0.0001), and Centers for Disease Control and Prevention (CDC) clinical stages C (P=0.005) and B (P=0.045), as compared with stage A, were associated with CD4 count <200 cells/microL. Nonetheless, no accurate algorithm for HAART initiation was found. Three hundred and three of the 615 patients were treated. Of these 303 patients, 79.5% showed an increase of >50 cells/microL in CD4 count 6 months after HAART initiation (median increase 128 cells/microL). Adherence >or=95% (P=0.022) and increase in absolute total lymphocyte count during follow-up (P<0.0001) were associated with a short-term positive immune response. CONCLUSIONS: Our results support the effectiveness of generic drug combinations in sub-Saharan Africa. In order to enhance the management of HIV disease in sub-Saharan Africa, efforts should target the development of low-cost CD4 cell count laboratory tests.
    [Abstract] [Full Text] [Related] [New Search]